Breast cancer statistics, 2019

This article is the American Cancer Society’s biennial update on female breast cancer statistics in the United States, including data on incidence, mortality, survival, and screening. Over the most recent 5‐year period (2012‐2016), the breast cancer incidence rate increased slightly by 0.3% per year, largely because of rising rates of local stage and hormone receptor‐positive disease. In contrast, the breast cancer death rate continues to decline, dropping 40% from 1989 to 2017 and translating to 375,900 breast cancer deaths averted. Notably, the pace of the decline has slowed from an annual decrease of 1.9% during 1998 through 2011 to 1.3% during 2011 through 2017, largely driven by the trend in white women. Consequently, the black–white disparity in breast cancer mortality has remained stable since 2011 after widening over the past 3 decades. Nevertheless, the death rate remains 40% higher in blacks (28.4 vs 20.3 deaths per 100,000) despite a lower incidence rate (126.7 vs 130.8); this disparity is magnified among black women aged <50 years, who have a death rate double that of whites. In the most recent 5‐year period (2013‐2017), the death rate declined in Hispanics (2.1% per year), blacks (1.5%), whites (1.0%), and Asians/Pacific Islanders (0.8%) but was stable in American Indians/Alaska Natives. However, by state, breast cancer mortality rates are no longer declining in Nebraska overall; in Colorado and Wisconsin in black women; and in Nebraska, Texas, and Virginia in white women. Breast cancer was the leading cause of cancer death in women (surpassing lung cancer) in four Southern and two Midwestern states among blacks and in Utah among whites during 2016‐2017. Declines in breast cancer mortality could be accelerated by expanding access to high‐quality prevention, early detection, and treatment services to all women.

[1]  L. Newman,et al.  Health Disparities and Triple-Negative Breast Cancer in African American Women: A Review , 2017, JAMA surgery.

[2]  Rebecca L. Siegel Mph,et al.  Cancer statistics, 2018 , 2018 .

[3]  C. Parise,et al.  Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California. , 2014, Cancer epidemiology.

[4]  B. Sommers,et al.  Changes in Mortality After Massachusetts Health Care Reform , 2014, Annals of Internal Medicine.

[5]  Eric J Feuer,et al.  The decrease in breast-cancer incidence in 2003 in the United States. , 2007, The New England journal of medicine.

[6]  Sung-Bae Kim,et al.  Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy , 2017, The New England journal of medicine.

[7]  Ruth Etzioni,et al.  Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[8]  Eric P. Winer,et al.  Breast Cancer Treatment: A Review , 2019, JAMA.

[9]  Peter W. Laird,et al.  Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas , 2017, JAMA oncology.

[10]  Ahmedin Jemal,et al.  Cancer treatment and survivorship statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[11]  K. McGuire,et al.  Are Mastectomies on the Rise? A 13-Year Trend Analysis of the Selection of Mastectomy Versus Breast Conservation Therapy in 5865 Patients , 2009, Annals of Surgical Oncology.

[12]  S. Ingles,et al.  Reproductive history, breast‐feeding and risk of triple negative breast cancer: The Breast Cancer Etiology in Minorities (BEM) study , 2018, International journal of cancer.

[13]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[14]  J. Gentleman,et al.  Update on mammography trends , 2011, Cancer.

[15]  O. Olopade,et al.  A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change , 2015, CA: a cancer journal for clinicians.

[16]  M. Hurlbert,et al.  Black:white disparities in breast cancer mortality in the 50 largest cities in the United States, 2005-2014. , 2016, Cancer epidemiology.

[17]  A. Jemal,et al.  Breast cancer subtypes among Eastern‐African–born black women and other black women in the United States , 2019, Cancer.

[18]  D. Silverman,et al.  Cancer incidence and mortality trends among whites in the United States, 1947-84. , 1987, Journal of the National Cancer Institute.

[19]  P. Cordeiro,et al.  Bilateral Mastectomy versus Breast-Conserving Surgery for Early-Stage Breast Cancer: The Role of Breast Reconstruction , 2015, Plastic and reconstructive surgery.

[20]  Abigail Silva,et al.  Racial/Ethnic Disparities in Time to a Breast Cancer Diagnosis: The Mediating Effects of Health Care Facility Factors , 2015, Medical care.

[21]  R. Barrett,et al.  Multilevel Examination of Health Disparity: The Role of Policy Implementation in Neighborhood Context, in Patient Resources, and in Healthcare Facilities on Later Stage of Breast Cancer Diagnosis , 2018, Cancer Epidemiology, Biomarkers & Prevention.

[22]  E. Winer,et al.  Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Gretchen L. Gierach,et al.  Pooled Analysis of Nine Cohorts Reveals Breast Cancer Risk Factors by Tumor Molecular Subtype. , 2018, Cancer research.

[24]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[25]  P. Fasching,et al.  Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer , 2019, The New England journal of medicine.

[26]  A. Jemal,et al.  Trends in stage at diagnosis for young breast cancer patients in the United States , 2018, Breast Cancer Research and Treatment.

[27]  Philip S Rosenberg,et al.  Incidence of breast cancer in the United States: current and future trends. , 2011, Journal of the National Cancer Institute.

[28]  R. Wolff,et al.  The Interaction between Genetic Ancestry and Breast Cancer Risk Factors among Hispanic Women: The Breast Cancer Health Disparities Study , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[29]  J. Lortet-Tieulent,et al.  Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. , 2015, JAMA.

[30]  R. Hiatt,et al.  Trends and disparities in socioeconomic and behavioural characteristics, life expectancy, and cause-specific mortality of native-born and foreign-born populations in the United States, 1979-2003. , 2006, International journal of epidemiology.

[31]  Kevin A. Henry,et al.  Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State , 2015, Journal of the National Cancer Institute.

[32]  J. Boughey,et al.  Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes , 2018, Annals of surgical oncology.

[33]  Timothy J Wilt,et al.  Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. , 2009, Annals of internal medicine.

[34]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[35]  Yu Shyr,et al.  Nationwide trends in mastectomy for early-stage breast cancer. , 2015, JAMA surgery.

[36]  Oguzhan Alagoz,et al.  Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. , 2014, Journal of the National Cancer Institute.

[37]  Virginia G Kaklamani,et al.  Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.

[38]  Richard J. K. Taylor,et al.  The impact of changes in hormone therapy on breast cancer incidence in the US population , 2009, Cancer Causes & Control.

[39]  N. Keating,et al.  Receipt of locoregional therapy among young women with breast cancer , 2012, Breast Cancer Research and Treatment.

[40]  A. Jemal,et al.  State Variation in the Receipt of a Contralateral Prophylactic Mastectomy Among Women Who Received a Diagnosis of Invasive Unilateral Early-Stage Breast Cancer in the United States, 2004-2012 , 2017, JAMA surgery.

[41]  L. Newman Parsing the Etiology of Breast Cancer Disparities. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  J. Martin,et al.  Births: Final Data for 2017. , 2018, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[43]  W. Satariano,et al.  Cancer Research in Asian American, Native Hawaiian, and Pacific Islander Populations: Accelerating Cancer Knowledge by Acknowledging and Leveraging Heterogeneity , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[44]  T. Wilt,et al.  Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. , 2009, Annals of internal medicine.

[45]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[46]  Ping Sun,et al.  Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. , 2015, JAMA.

[47]  H. Nelson,et al.  Incident Cases Captured in the National Cancer Database Compared with Those in U.S. Population Based Central Cancer Registries in 2012–2014 , 2019, Annals of Surgical Oncology.

[48]  S. Gomez,et al.  Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[49]  Oguzhan Alagoz,et al.  Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012 , 2018, JAMA.

[50]  A. Jemal,et al.  Breast Cancer Incidence Rates in U.S. Women Are No Longer Declining , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[51]  L. Mobley,et al.  Update on triple‐negative breast cancer disparities for the United States: A population‐based study from the United States Cancer Statistics database, 2010 through 2014 , 2019, Cancer.

[52]  S. Altekruse,et al.  The impact of follow-up type and missed deaths on population-based cancer survival studies for Hispanics and Asians. , 2014, Journal of the National Cancer Institute. Monographs.

[53]  Jennifer L. Caswell-Jin,et al.  Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review , 2018, JNCI cancer spectrum.

[54]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .

[55]  W. Gradishar,et al.  Triple-Negative Breast Cancer: Current Practice and Future Directions. , 2017, Journal of oncology practice.

[56]  N. Howlader,et al.  Differences in Breast Cancer Survival by Molecular Subtypes in the United States , 2018, Cancer Epidemiology, Biomarkers & Prevention.

[57]  Vanessa M. Hubbard-Lucey,et al.  Immunotherapy and targeted therapy combinations in metastatic breast cancer. , 2019, The Lancet. Oncology.

[58]  M. Gail,et al.  Proportion of U.S. Trends in Breast Cancer Incidence Attributable to Long-term Changes in Risk Factor Distributions , 2018, Cancer Epidemiology, Biomarkers & Prevention.